Figure 6. Tumor dimensions after the inhibition of telomerase.

CRL 1687cells were injected subcutaneously to nude athymic mice, which were treated three times a week with telomerase inhibitor, GRN163L or with PBS as a control. a. Average tumor sizes of the two groups of mice (each contained 18 mice) which were measured every week. b. Each group of mice was subsequently divided into three subgroups: one treated with PBS or GRN163L only, the other treated with doxorubicin and PBS or GRN163L, and a group treated with vincristine and PBS or GRN163L. The sizes of xenografts were measure each week. c. In vivo telomere shortening after GRN163L administration. Nude athymic mice were injected with CRL1687 cells subcutaneously and treated with telomerase inhibitor, GRN163L, or PBS. Telomere length was evaluated by Southern blot. M- molecular size marker (sizes are listed on the left). Numbers below the gel indicate average telomere length in KB and the extent of telomere shortening. 5 samples of each cell type were analyzed. D. Graphical representation of telomere shortening in vivo after telomerase inhibition with GRN163L. TRF- terminal repeats fragment indicated the length of telomeres. The telomeres shortened by ∼40% after telomerase inhibition. The experiment was repeated twice with 5 samples of each cell types.